Clinical trial Recruiting at 2 sites Interventional Ages 18 to 45 Women only

Right DLPFC fNIRS neurofeedback for anxiety in women with recurrent pregnancy loss

Official title: Right Dorsolateral Prefrontal Cortex-Targeted fNIRS-BCI Closed-loop Neurofeedback for Anxiety Relief and Cardiac Autonomic Regulation in Women With Recurrent Pregnancy Loss: a Randomized, Sham-controlled Clinical Trial

Run by Shenyang Medical College · NCT07325370 · Data updated 2026-11-12

This trial will see if right dorsolateral prefrontal cortex-targeted fNIRS closed-loop neurofeedback with slow-wave sound cues can reduce anxiety and improve heart-rate regulation in women with recurrent pregnancy loss aged 18–45.

More Anxiety trials

Quick facts

Study typeInterventional
Ages18 Years to 45 Years
SexWomen only
Enrollment62 (estimated)
SponsorShenyang Medical College
Academic / other
Locations2 sites (Shenyang, Liaoning and 1 other locations)
StatusRecruiting
StartedDecember 29, 2025
Main results expectedOctober 30, 2026
Study endsOctober 30, 2026
Registry record updatedApril 24, 2026
Trial IDNCT07325370 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18–45 who are right-handed, have recurrent pregnancy loss (≥2 consecutive losses before 28 weeks), are not currently pregnant (or are in a missed miscarriage state), meet DSM-5 criteria for an anxiety disorder with CGI-S ≥4, and have HAMA ≥16 with HAMD-17 <17.

Probably not a fit

Patients with unstable blood pressure, significant organic or neurological comorbidities, high suicide risk, major uncontrolled medical illnesses, or currently pregnant are unlikely to be eligible or to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, sham-controlled, parallel-group trial comparing real versus sham right DLPFC-targeted fNIRS-BCI closed-loop neurofeedback delivered with slow-wave acoustic cueing in women with recurrent pregnancy loss and comorbid anxiety. Participants will be randomized 1:1 to real or sham feedback with identical visit structure, and fNIRS will be recorded across all training sessions while ECG is recorded during the first formal session. Primary clinical outcomes focus on anxiety severity and treatment response (≥50% reduction in HAMA) measured at end of treatment and at 3-month follow-up, with safety monitoring of adverse events. Mechanistic analyses will examine right DLPFC activation and short-term brain–heart coupling via fNIRS and ECG data.

Why it matters

Potential benefit: If successful, the intervention could meaningfully reduce anxiety symptoms and improve cardiac autonomic regulation in affected women, potentially lowering stress-related reproductive risk factors.

How similar studies have gone: Neurofeedback and brain–computer interface approaches have shown preliminary promise for anxiety and autonomic regulation in small or early-phase studies, but right DLPFC-targeted fNIRS-BCI closed-loop approaches remain novel with limited randomized evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* (i) Women aged 18-45 years, right-handed;
* (ii) Diagnosis of recurrent pregnancy loss (RPL), defined as ≥2 consecutive spontaneous pregnancy losses occurring before 28 weeks of gestation;
* (iii) Not currently pregnant, or currently in a missed miscarriage state;
* (iv) Meet DSM-5 diagnostic criteria for an anxiety disorder, with at least moderate severity, defined as Clinical Global Impression-Severity (CGI-S) ≥4;
* (v) Hamilton Anxiety Rating Scale (HAMA) ≥16, with 17-item Hamilton Depression Rating Scale (HAMD-17) \<17, to ensure anxiety is the predominant affective disturbance.

Exclusion Criteria:

* (i) Markedly unstable blood pressure (systolic BP \>180 mmHg or \<90 mmHg);
* (ii) Clinically important comorbid organic diseases, including but not limited to hyperthyroidism, history of atrial fibrillation, sinus bradycardia, major neurological disorders, cerebrovascular disease, or severe pulmonary disease;
* (iii) Significant suicide risk, judged by psychiatric assessment to be unsuitable for study participation;
* (iv) Other severe psychiatric disorders, including substance use disorder, schizophrenia, delusional disorder, unspecified psychotic disorder, bipolar disorder, or delirium;
* (v) Use of any oral antidepressant, anxiolytic, or antipsychotic medication within the past 4 weeks, or fluoxetine within the past 6 weeks, or any long-acting injectable antipsychotic within the past 3 months.

Where it's running

  • The Second Affiliated Hospital of Shenyang Medical College
    Shenyang, Liaoning, China
    Recruiting
  • Central Hospital Affiliated to Shenyang Medical College
    Shenyang, Liaoning, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.